

July 23, 2018

Change in Rotavirus Vaccine

Ontario is changing rotavirus vaccine product from Rotarix[®] to RotaTeg[®]. Both vaccines have similar safety profiles and neither vaccine contains potential allergens. The National Advisory Committee on Immunization (NACI) recommends routine infant rotavirus vaccination with either of the rotavirus vaccine products.

Please continue to order publicly funded vaccine through OGPMSS. [http://www.forms.ssb.gov.on.ca/mbs/ssb/forms/ssbforms.nsf/AttachDownloadV2?openagent&T M=9 47 14 AM&ENV=ODAE&NO=014-2203-64E&SEQ=7&VER=11]

Rotarix [®] by GlaxoSmithKline Inc.	RotaTeq [®] by <i>Merck Canada Inc</i> .
 live, attenuated, monovalent (Rot-1) 1.5 mL oral dose 2 doses, given at least 4 weeks apart routinely given at 2 and 4 months of age 	 live, attenuated, pentavalent (Rot-5) 2.0 mL oral dose 3 doses, given at least 4 to 10 weeks apart routinely given at 2, 4 and 6 months of age

Please complete the infant series using the same product, whenever possible. In the event that Rotarix[®] is not available or if the product used for the first dose is unknown, used RotaTeg[®] for a total of three doses (refer to NACI).

Scenarios for completing the rotavirus vaccine series

- 1. For infants who received one-dose of Rot-1:
 - a) provide a second dose of Rot-1 to complete the series
 - b) if Rot-1 is unavailable, provide Rot-5 at four months and again at six months of age
 - c) if the product for the first dose is unknown, provide Rot-5 at four months and again at six months of age
- For infants not started on rotavirus:
 - a) start them on Rot-5 at two, four and six months of age

All rotavirus vaccine doses should be administered before 8 months of age. If an incomplete dose is administered (e.g. infant spits or regurgitates the vaccine) do NOT give a replacement dose. See product monograph for more detail.

Health care providers should report intussusception in the first 21 days following any dose of rotavirus vaccine to Toronto Public Health at 416-338-2030.